Raymond James Cuts Xilio Therapeutics (NASDAQ:XLO) Price Target to $4.00

Xilio Therapeutics (NASDAQ:XLO) had its target price lowered by Raymond James from $6.00 to $4.00 in a report published on Friday,Benzinga reports. The firm currently has an outperform rating on the stock.

Xilio Therapeutics Price Performance

NASDAQ XLO traded down $0.05 during trading hours on Friday, hitting $0.99. The company had a trading volume of 206,853 shares, compared to its average volume of 539,527. Xilio Therapeutics has a fifty-two week low of $0.49 and a fifty-two week high of $1.93. The company has a market capitalization of $43.51 million, a price-to-earnings ratio of -0.47 and a beta of -0.24. The firm’s 50 day moving average is $0.88 and its 200 day moving average is $0.95.

Xilio Therapeutics (NASDAQ:XLO) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.01). The company had revenue of $2.36 million during the quarter, compared to analysts’ expectations of $30.00 million. On average, equities analysts anticipate that Xilio Therapeutics will post -1.26 EPS for the current year.

Institutional Trading of Xilio Therapeutics

An institutional investor recently bought a new position in Xilio Therapeutics stock. XTX Topco Ltd bought a new stake in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 33,289 shares of the company’s stock, valued at approximately $32,000. XTX Topco Ltd owned approximately 0.08% of Xilio Therapeutics at the end of the most recent reporting period. Institutional investors own 54.29% of the company’s stock.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.